Atika Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,339	Closed	-$4.11M	–	62
2025 Q4	$4.11M	Sell	10,339 -11,867	-53%	-$5.25M	0.57%	64
2025 Q3	$10.1M	Sell	22,206 -5,494	-20%	-$2.24M	0.86%	37
2025 Q2	$9.03M	Buy	+27,700	New	+$7.66M	0.94%	32
2024 Q4	–	Sell	-31,000	Closed	-$8.53M	–	87
2024 Q3	$8.53M	Buy	31,000 +6,500	+27%	+$1.69M	0.91%	41
2024 Q2	$5.95M	Buy	+24,500	New	+$3.87M	0.69%	57
2021 Q4	–	Sell	-64,000	Closed	-$12.1M	–	90
2021 Q3	$12.1M	Buy	+64,000	New	+$12M	0.86%	51
2018 Q3	–	Sell	-23,000	Closed	-$2.27M	–	87
2018 Q2	$2.27M	Sell	23,000 -18,000	-44%	-$1.79M	0.65%	73
2018 Q1	$4.88M	Buy	41,000 +16,000	+64%	+$2.06M	1.94%	26
2017 Q4	$3.18M	Hold	25,000	–	–	1.36%	38
2017 Q3	$2.94M	Buy	+25,000	New	+$2.13M	1.2%	48
2016 Q4	–	Sell	-22,000	Closed	-$1.49M	–	58
2016 Q3	$1.49M	Buy	22,000 +8,000	+57%	+$564K	0.74%	57
2016 Q2	$777K	Buy	+14,000	New	+$882K	0.42%	58
2015 Q3	–	Sell	-24,000	Closed	-$2.88M	–	61
2015 Q2	$2.88M	Buy	24,000 +18,500	+336%	+$2.21M	1.38%	34
2015 Q1	$574K	Buy	+5,500	New	+$557K	0.39%	58
2014 Q3	–	Sell	-20,000	Closed	-$1.26M	–	66
2014 Q2	$1.26M	Buy	+20,000	New	+$1.19M	1.11%	41